Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.
Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. nenatis vitae, justo.
Discover and track the wide-ranging implications of COVID-19 on biopharma, including share price shifts, drug sales results, the clinical trials at risk of delay or cancellation, changes to timelines and costs, the effect on deals, and ultimately what this all means for the commercial potential of assets across every indication.
In addition, EvaluatePharma Vision’s exclusive predictive analytics provide unique insights into the clinical pipeline for COVID-19. So you can discover each product’s probability of approval, expected trial costs and clinical milestones, or benchmark against previous pandemics.
Shown alongside industry, indication, mechanism of action and technology benchmarks, the product-specific PTRS model analyzes over 34,000 historical phase transitions to understand the predictive power of 50+ attributes to deliver insight into the risk profile of an individual product.
For COVID-19 you can identify which treatments and assets have the best chance of getting approved and making a difference in the battle against the virus.
You can view costs at a trial, drug or indication level. It provides fully transparent R&D cost benchmarks by indication and phase so you can benchmark expenditure, judge your risk exposure, or see where competitors are focusing investment.
Vision’s unique R&D costs cover all commercially relevant COVID-19 trials, so you can understand which companies are most active in this space and how much spend they are committing.
NPV Analyzer provides instant product and company valuations, combining the risk and return in a single view of an asset's value.
Covering over 6,000 products, you can identify which to prioritize in your own portfolio, or confidently value potential licensing options and investment decisions.
Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.
Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. nenatis vitae, justo.
Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.
Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. nenatis vitae, justo.
Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.
Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. nenatis vitae, justo.
Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.
Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. nenatis vitae, justo.
Scrutinise the clinical trial results of active products of interest down to the endpoint level, with aggregated and standardised trial outcomes.
It combines information from multiple sources to produce proprietary endpoint analysis focused on the four indication-specific endpoints most likely to lead to regulatory approval.
EvaluatePharma Vision’s consistent proprietary methodology helps to predict US and EU approval dates for all NMEs in clinical development, even early-stage assets not covered by brokers.
It includes time-in-phase benchmarks for 840+ indications, with a fully transparent audit of how these are calculated for each phase.
 |
 |
 |
|
|---|---|---|---|
| Stimulus | |||
| Daily news with expert analysis |  |
|
|
| Interviews with industry leaders | |
|
|
| Company & product events coverage | |
|
|
| Response | |||
| Consensus forecasts to 2024 |  |
|
|
| Archived consensus forecasts | |
|
|
| Sales by indication | |
|
|
| Therapy area, mechanism of action, and other classifications | |
|
|
| Licensing deals, M&A, venture financing and IPOs | |
|
|
| Orphan drugs and biosimilars analysis | |
|
|
| Success rate benchmarks (PTRS) |  |
||
| Time-in-phase benchmarks by indication | |
||
| Comprehensive product and trial level R&D costs | |
||
| Clinical trials design and outcomes | |
||
| Net Present Value calculator | |
||
| Calendar of market events and catalysts | |